“…Although platelets from patients with diabetes have altered function, it is unclear what, if any, impact that finding has on the required dose of aspirin for cardioprotective outcomes in the diabetic patient (29). Many alternate pathways exist for platelet activation and aggregation (adenosine diphosphate, thrombin, epinephrine, von Willebrand factor) that are independent of thromboxane A2 and thus not sensitive to the effects of aspirin (30).…”